Imfinzi, the first drug of AstraZeneca’s PD-L1 antibody Durvalumab, was approved by the US FDA in 2017 for the treatment of advanced metastatic urothelial cancer. Urothelial cancer actually accounts for up to 90% of the entire bladder cancer population. The incidence of bladder cancer is very high in both the United States and China. The United States ranks among the top five in terms of incidence. In China, bladder cancer is among the top ten most common cancers among men.
The five-year survival rate of bladder cancer is actually relatively low. If it is early-stage bladder cancer, the five-year survival rate is 98%, and when it develops into late-stage bladder cancer, the five-year survival rate suddenly drops to 15%, and the prognosis is not optimistic. .
1. First introduce the Durvalumab antibody drug I
Durvalumab is another new drug approved by the US FDA in 2017 for the treatment of bladder cancer, targeting metastatic urothelial cancer or locally advanced tumors. Cancer patients. Especially for patients who have progressed after platinum-based chemotherapy. Durvalumab was administered in a single-arm clinical trial of 182 patients with advanced metastatic urothelial cancer at a dose of 10 mg/kg administered intravenously over 60 minutes every two weeks, with the most patients taking the drug for one year.
Common side effects:
After taking the medicine, you may experience fatigue, pain, loss of appetite, nausea, urinary tract infection, etc. If new serious side effects occur, close clinical follow-up and symptomatic treatment are required. Immune or infectious adverse reactions may also occur as follows: pneumonia, enteritis, hepatitis, etc.
2. Action mechanism of AstraZeneca’s PD-L1 antibody Imfinzi
PD-L1 expression is induced by the expression of inflammatory signals and expressed on tumor-related cells. PD-L1 blocks T cell function and activation through the interaction of PD-1 and CD80. Durvalumab is a human immunoglobulin monoclonal antibody that blocks PD-L1 and the interaction of PD-1 and CD80.
3. AstraZeneca’s PD-L1 antibody Imfinzi is approved for non-small cell lung cancer
This year, Imfinzi was approved by the US FDA for use in stage III non-small cell lung cancer that cannot be treated with surgery, radiotherapy, or chemotherapy. Patients in stable condition. Imfinzi is the first maintenance therapy for stage III lung cancer to be marketed after radiotherapy and chemotherapy, with a PFS of 16.8. Intravenous injection solutions include:
500 mg/10mL (50 mg/mL) solution in disposable-dose vials
120 mg/2.4mL (50 mg/mL) solution in Disposable-dose vials
The launch of AstraZeneca’s PD-L1 antibody Durvalumab I drug Imfinzi means that there are currently five new PD-1/PD-L1 anti-cancer drugs on the market. .
They are: MSD Keytruda (K drug), BMS Opdivo (O drug), Roche Tecentriq atezolizumab (T drug), Pfizer Merck’s Bavencio (B drug), AstraZeneca’s PD-L1 antibody Durvalumab (I drug).
Many patients and family members will ask which PD-1/PD-L1 to choose for treatment? Because different new anti-cancer drugs have the same indications, that is, the same cancer can be treated with both K and O drugs as well as T drugs. However, these three new anti-cancer drugs cannot be mixed. How to choose and define them?
The specific type of PD-1 or PD-L1 treatment needs to be clarified by submitting a written consultation or face-to-face consultation, because both PD1 and PD-L1 are prescription drugs and need to be submitted one-to-one to the authoritative oncology department in Hong Kong. Only a consultation with a doctor will make it clear.
Generally, the results will be obtained after 2-3 working written consultations. If you want to bring the patient or family member with the patient's information for an in-person consultation, you need to make an appointment 5 days in advance. Ruisi International HPV2030 will arrange the appointment and send the appointment confirmation information.
The above-mentioned drugs all need to be transported under cold chain conditions at 2-8 degrees Celsius, so the cold chain must be prepared when carrying drugs. At the same time, biological drugs cannot be shaken violently. There is no problem with shaking when you carry them. Please inform them when disposing. The nurse should not shake violently.